• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
SPL
Click for more information
0.00% 10.5¢

STARPHARMA HOLDINGS LIMITED - Announcements

Market Cap $43.82M  ! watchlist Created with Sketch. Add to my watchlist

Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The... Starpharma Holdings Limited is an Australia-based biopharmaceutical company. The principal activities of the Company consist of research, development and commercialization of dendrimer products for pharmaceutical, life-science and other applications. It is focused on developing and commercializing novel therapeutic products that address global healthcare needs. The Company is also involved in the development of nano-scale materials, including the development of VivaGel for the management and prevention of bacterial vaginosis, and as an antiviral condom coating, and VIRALEZE, an antiviral nasal spray. The Company is also applying its proprietary dendrimers to drug delivery to create improved pharmaceuticals and has developed the valuable DEP delivery platform. VIRALEZE is a broad-spectrum nasal spray intended to provide a moisturizing and protective barrier in the nose that traps and blocks cold/respiratory viruses. It also offers VivaGel BV and VivaGel Condom products.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
SPL Appendix 3B19/03/19
SPL Shareholder Update March 201918/03/19
SPL Starpharma receives $4.0M R&D tax incentive refundPRICE SENSITIVE12/03/19
SPL Interim Report and Half-Yearly Financial ResultsPRICE SENSITIVE27/02/19
SPL Appendix 3B08/02/19
SPL Quarterly Cashflow ReportPRICE SENSITIVE30/01/19
SPL Shareholder Update January 201917/01/19
SPL Becoming a substantial holder14/01/19
SPL Response to ASX Aware LetterPRICE SENSITIVE07/01/19
SPL VivaGel condom receives final regulatory approval in JapanPRICE SENSITIVE02/01/19
SPL Change in Director's Interest Notice - P Turvey28/12/18
SPL Change in Director's Interest Notice - J Fairley28/12/18
SPL Change in Director's Interest Notice - R Thomas28/12/18
SPL US FDA requests further data for VivaGel BV approvalPRICE SENSITIVE27/12/18
SPL Ceasing to be a substantial holder27/12/18
SPL US VivaGel BV licensed for A$142M milestones plus royaltiesPRICE SENSITIVE20/12/18
SPL US patent granted for SPL7013 eye drops for conjunctivitis12/12/18
SPL Change in Director's Interest Notice - J Fairley11/12/18
SPL Appendix 3B11/12/18
SPL Becoming a substantial holder11/12/18
SPL AGM Results29/11/18
SPL AGM - Chairman address and CEO presentationPRICE SENSITIVE29/11/18
SPL DEP products outperform in human pancreatic cancer modelPRICE SENSITIVE16/11/18
SPL Appendix 3B05/11/18
SPL Notice of General Meeting/Proxy Form26/10/18
SPL Quarterly Cashflow ReportPRICE SENSITIVE26/10/18
SPL Starpharma Investor Presentation for Citi ConferencePRICE SENSITIVE17/10/18
SPL Ceasing to be a substantial holder08/10/18
SPL Change in Director's Interest Notice - J Fairley05/10/18
SPL Appendix 3B05/10/18
SPL Notification of AGM date02/10/18
SPL Change in substantial holding14/09/18
SPL DEP irinotecan outperforms in pancreatic cancer modelPRICE SENSITIVE05/09/18
SPL AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacyPRICE SENSITIVE31/08/18
SPL Appendix 4G - Corporate Governance Statement21/08/18
SPL Annual report and full year financial resultsPRICE SENSITIVE21/08/18
SPL Quarterly Cashflow ReportPRICE SENSITIVE17/07/18 download Created with Sketch. 227.14KB
SPL VivaGel BV NDA advances to next stage of FDA reviewPRICE SENSITIVE09/07/18 download Created with Sketch. 119.38KB
SPL Starpharma licenses VivaGel BV to Mundipharma for EuropePRICE SENSITIVE27/06/18 download Created with Sketch. 141.64KB
SPL Change in substantial holding06/06/18 download Created with Sketch. 534.98KB
SPL Change in Director's Interest Notice - R Thomas17/05/18
SPL Mundipharma licenses Starpharma's VivaGel BVPRICE SENSITIVE03/05/18
SPL Appendix 4C - Quarterly Cashflow ReportPRICE SENSITIVE30/04/18
SPL Starpharma completes US New Drug Application for VivaGel BVPRICE SENSITIVE30/04/18
SPL Starpharma to present at OTCQX Virtual Investor Conference11/04/18
SPL Change in Director's Interest Notice - J Fairley21/03/18
SPL Change in Director's Interest Notice - R Thomas20/03/18
SPL Appendix 3B20/03/18
SPL Change in Director's Interest Notice - R Thomas15/03/18
SPL Change in Director's Interest Notice - P Turvey12/03/18
SPL Change in Director's Interest Notice - J Fairley12/03/18
SPL Change in Director's Interest Notice - R Thomas05/03/18
SPL Interim Report and Half-Yearly Financial ResultsPRICE SENSITIVE26/02/18
SPL Starpharma receives $3.7M R&D tax incentive refundPRICE SENSITIVE22/02/18
SPL Shareholder Update February 201819/02/18
SPL Starpharma to commence DEP cabazitaxel phase 1/2 trialPRICE SENSITIVE31/01/18
SPL Appendix 3B29/01/18
SPL Appendix 4C - Quarterly Cashflow ReportPRICE SENSITIVE25/01/18
SPL VivaGel BV treatment clinical submission under rolling NDAPRICE SENSITIVE21/12/17
SPL Change in Director's Interest Notice - J Fairley11/12/17
SPL Appendix 3B11/12/17
SPL Change in Director's Interest Notice - R Thomas05/12/17
SPL Amended Constitution29/11/17
SPL AGM Results29/11/17
SPL AGM - Chairman address and CEO presentation29/11/17
SPL NDA submission for VivaGel BV in the USPRICE SENSITIVE21/11/17
SPL Change in Director's Interest Notice - J Fairley08/11/17
SPL Change in Director's Interest Notice - R Thomas31/10/17
SPL Notice of Annual General Meeting/Proxy Form27/10/17
SPL Appendix 4C - Quarterly Cashflow ReportPRICE SENSITIVE26/10/17
SPL VivaGel BV granted marketing approval in AustraliaPRICE SENSITIVE25/10/17
SPL Shareholder Update October 201718/10/17
SPL Appendix 3B12/10/17
SPL Starpharma and Peter Mac Cancer Centre awarded DEP GrantPRICE SENSITIVE09/10/17
SPL Change in Director's Interest Notice - J Fairley05/10/17
SPL Appendix 3B05/10/17
SPL Notification of AGM date02/10/17
SPL AstraZeneca presents 1st DEP candidate as Bcl2/xL inhibitorPRICE SENSITIVE28/09/17
SPL DEP docetaxel positive phase 1 results, phase 2 commencesPRICE SENSITIVE22/09/17
SPL Appendix 4G - Corporate Governance Statement28/08/17
SPL Annual report and full year financial resultsPRICE SENSITIVE28/08/17
SPL Starpharma to present at Finance News Network Investor Event24/08/17
SPL Appendix 3B21/08/17
SPL Starpharma and Monash awarded STEM Business FellowshipsPRICE SENSITIVE09/08/17
SPL Successful VivaGel Phase 3 results and NDA planned for rBVPRICE SENSITIVE07/08/17
SPL Appendix 4C - Quarterly Cashflow ReportPRICE SENSITIVE19/07/17
SPL Shareholder Update July 201704/07/17
SPL VivaGel BV phase 3 results timing and commercialisationPRICE SENSITIVE04/07/17
SPL Appendix 3B14/06/17
SPL Sale of Agrochemicals Business Investor Presentation14/06/17
SPL Starpharma sells Agrochemicals business to Agrium for $35MPRICE SENSITIVE14/06/17
SPL DEP irinotecan outperforms irinotecan in cancer modelsPRICE SENSITIVE06/06/17
SPL Starpharma receives DEP milestone from AstraZeneca02/06/17
SPL Appendix 4C - Quarterly Cashflow ReportPRICE SENSITIVE28/04/17
SPL AstraZeneca DEP candidate advance triggers milestone to SPLPRICE SENSITIVE20/04/17
SPL Ansell launches VivaGel condom in CanadaPRICE SENSITIVE12/04/17
SPL VivaGel BV phase 3 trials for prevention of BV completedPRICE SENSITIVE30/03/17
SPL Interim Report and Half-Year Financial ResultsPRICE SENSITIVE27/02/17
SPL Appendix 4C - Quarterly Cashflow ReportPRICE SENSITIVE31/01/17
SPL Appendix 3B25/01/17
SPL Appendix 3B
19/03/19
SPL Shareholder Update March 2019
18/03/19
SPL Starpharma receives $4.0M R&D tax incentive refund
12/03/19PRICE SENSITIVE
SPL Interim Report and Half-Yearly Financial Results
27/02/19PRICE SENSITIVE
SPL Appendix 3B
08/02/19
SPL Quarterly Cashflow Report
30/01/19PRICE SENSITIVE
SPL Shareholder Update January 2019
17/01/19
SPL Becoming a substantial holder
14/01/19
SPL Response to ASX Aware Letter
07/01/19PRICE SENSITIVE
SPL VivaGel condom receives final regulatory approval in Japan
02/01/19PRICE SENSITIVE
SPL Change in Director's Interest Notice - P Turvey
28/12/18
SPL Change in Director's Interest Notice - J Fairley
28/12/18
SPL Change in Director's Interest Notice - R Thomas
28/12/18
SPL US FDA requests further data for VivaGel BV approval
27/12/18PRICE SENSITIVE
SPL Ceasing to be a substantial holder
27/12/18
SPL US VivaGel BV licensed for A$142M milestones plus royalties
20/12/18PRICE SENSITIVE
SPL US patent granted for SPL7013 eye drops for conjunctivitis
12/12/18
SPL Change in Director's Interest Notice - J Fairley
11/12/18
SPL Appendix 3B
11/12/18
SPL Becoming a substantial holder
11/12/18
SPL AGM Results
29/11/18
SPL AGM - Chairman address and CEO presentation
29/11/18PRICE SENSITIVE
SPL DEP products outperform in human pancreatic cancer model
16/11/18PRICE SENSITIVE
SPL Appendix 3B
05/11/18
SPL Notice of General Meeting/Proxy Form
26/10/18
SPL Quarterly Cashflow Report
26/10/18PRICE SENSITIVE
SPL Starpharma Investor Presentation for Citi Conference
17/10/18PRICE SENSITIVE
SPL Ceasing to be a substantial holder
08/10/18
SPL Change in Director's Interest Notice - J Fairley
05/10/18
SPL Appendix 3B
05/10/18
SPL Notification of AGM date
02/10/18
SPL Change in substantial holding
14/09/18
SPL DEP irinotecan outperforms in pancreatic cancer model
05/09/18PRICE SENSITIVE
SPL AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy
31/08/18PRICE SENSITIVE
SPL Appendix 4G - Corporate Governance Statement
21/08/18
SPL Annual report and full year financial results
21/08/18PRICE SENSITIVE
SPL Quarterly Cashflow Report
17/07/18PRICE SENSITIVE download Created with Sketch. 227.14KB
SPL VivaGel BV NDA advances to next stage of FDA review
09/07/18PRICE SENSITIVE download Created with Sketch. 119.38KB
SPL Starpharma licenses VivaGel BV to Mundipharma for Europe
27/06/18PRICE SENSITIVE download Created with Sketch. 141.64KB
SPL Change in substantial holding
06/06/18 download Created with Sketch. 534.98KB
SPL Change in Director's Interest Notice - R Thomas
17/05/18
SPL Mundipharma licenses Starpharma's VivaGel BV
03/05/18PRICE SENSITIVE
SPL Appendix 4C - Quarterly Cashflow Report
30/04/18PRICE SENSITIVE
SPL Starpharma completes US New Drug Application for VivaGel BV
30/04/18PRICE SENSITIVE
SPL Starpharma to present at OTCQX Virtual Investor Conference
11/04/18
SPL Change in Director's Interest Notice - J Fairley
21/03/18
SPL Change in Director's Interest Notice - R Thomas
20/03/18
SPL Appendix 3B
20/03/18
SPL Change in Director's Interest Notice - R Thomas
15/03/18
SPL Change in Director's Interest Notice - P Turvey
12/03/18
SPL Change in Director's Interest Notice - J Fairley
12/03/18
SPL Change in Director's Interest Notice - R Thomas
05/03/18
SPL Interim Report and Half-Yearly Financial Results
26/02/18PRICE SENSITIVE
SPL Starpharma receives $3.7M R&D tax incentive refund
22/02/18PRICE SENSITIVE
SPL Shareholder Update February 2018
19/02/18
SPL Starpharma to commence DEP cabazitaxel phase 1/2 trial
31/01/18PRICE SENSITIVE
SPL Appendix 3B
29/01/18
SPL Appendix 4C - Quarterly Cashflow Report
25/01/18PRICE SENSITIVE
SPL VivaGel BV treatment clinical submission under rolling NDA
21/12/17PRICE SENSITIVE
SPL Change in Director's Interest Notice - J Fairley
11/12/17
SPL Appendix 3B
11/12/17
SPL Change in Director's Interest Notice - R Thomas
05/12/17
SPL Amended Constitution
29/11/17
SPL AGM Results
29/11/17
SPL AGM - Chairman address and CEO presentation
29/11/17
SPL NDA submission for VivaGel BV in the US
21/11/17PRICE SENSITIVE
SPL Change in Director's Interest Notice - J Fairley
08/11/17
SPL Change in Director's Interest Notice - R Thomas
31/10/17
SPL Notice of Annual General Meeting/Proxy Form
27/10/17
SPL Appendix 4C - Quarterly Cashflow Report
26/10/17PRICE SENSITIVE
SPL VivaGel BV granted marketing approval in Australia
25/10/17PRICE SENSITIVE
SPL Shareholder Update October 2017
18/10/17
SPL Appendix 3B
12/10/17
SPL Starpharma and Peter Mac Cancer Centre awarded DEP Grant
09/10/17PRICE SENSITIVE
SPL Change in Director's Interest Notice - J Fairley
05/10/17
SPL Appendix 3B
05/10/17
SPL Notification of AGM date
02/10/17
SPL AstraZeneca presents 1st DEP candidate as Bcl2/xL inhibitor
28/09/17PRICE SENSITIVE
SPL DEP docetaxel positive phase 1 results, phase 2 commences
22/09/17PRICE SENSITIVE
SPL Appendix 4G - Corporate Governance Statement
28/08/17
SPL Annual report and full year financial results
28/08/17PRICE SENSITIVE
SPL Starpharma to present at Finance News Network Investor Event
24/08/17
SPL Appendix 3B
21/08/17
SPL Starpharma and Monash awarded STEM Business Fellowships
09/08/17PRICE SENSITIVE
SPL Successful VivaGel Phase 3 results and NDA planned for rBV
07/08/17PRICE SENSITIVE
SPL Appendix 4C - Quarterly Cashflow Report
19/07/17PRICE SENSITIVE
SPL Shareholder Update July 2017
04/07/17
SPL VivaGel BV phase 3 results timing and commercialisation
04/07/17PRICE SENSITIVE
SPL Appendix 3B
14/06/17
SPL Sale of Agrochemicals Business Investor Presentation
14/06/17
SPL Starpharma sells Agrochemicals business to Agrium for $35M
14/06/17PRICE SENSITIVE
SPL DEP irinotecan outperforms irinotecan in cancer models
06/06/17PRICE SENSITIVE
SPL Starpharma receives DEP milestone from AstraZeneca
02/06/17
SPL Appendix 4C - Quarterly Cashflow Report
28/04/17PRICE SENSITIVE
SPL AstraZeneca DEP candidate advance triggers milestone to SPL
20/04/17PRICE SENSITIVE
SPL Ansell launches VivaGel condom in Canada
12/04/17PRICE SENSITIVE
SPL VivaGel BV phase 3 trials for prevention of BV completed
30/03/17PRICE SENSITIVE
SPL Interim Report and Half-Year Financial Results
27/02/17PRICE SENSITIVE
SPL Appendix 4C - Quarterly Cashflow Report
31/01/17PRICE SENSITIVE
SPL Appendix 3B
25/01/17
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
10.5¢ 		Change
0.000(0.00%) 		Mkt cap ! $43.82M
Open High Low Value Volume
10.5¢ 11.5¢ 10.0¢ $110.6K 1.006M

Buyers (Bids)

No. Vol. Price($)
1 83046 10.5¢
 

Sellers (Offers)

Price($) Vol. No.
11.0¢ 30000 1
View Market Depth
Last trade - 16.10pm 15/11/2024 (20 minute delay) ?
Last
10.5¢ 		  Change
0.000 ( 5.00 %)
Open High Low Volume
10.3¢ 11.5¢ 10.3¢ 347942
Last updated 15.58pm 15/11/2024 ?
SPL (ASX) Chart

Top Stories

HotCopper Highlights: Your most watched stocks for Week 46, 2024

What you - HotCopper users - were most interested in viewing and discussing this week (Week 46 of the year!)
Banshee's historic trenches prove rich in antimony and gold for GDM Great Divide Mining Ltd has found high-grade antimony and gold through geochemical sampling at its Banshee prospect in Queensland
InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain InhaleRX Ltd has received approval for a Phase 2 clinical trial to test its novel therapy IRX-211 for treatment of Breakthrough Cancer Pain
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
Cyclone signs MOU with Vale for development of Iron Bear play Cyclone Metals Lt has signed a Memorandum of Understanding with Vale S.A to support development of the former's iron ore project in Canada
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.